Perfluorinated compounds: Emerging POPs with potential immunotoxicity

Toxicology Letters

Volumn 230, Issue 2, 2014, Pages 263-270

  Corsini, Emanuela ^a   Luebke, Robert W ^b   Germolec, Dori R ^c   DeWitt, Jamie C ^d  

^a UNIVERSITY OF MILAN   (Italy)

^b U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^d EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Cytokine; Immunosuppression; Perfluorinated compounds; PPAR receptor; Vaccination

Indexed keywords

PERFLUORO COMPOUND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; ALKANESULFONIC ACID; FLUOROCARBON; OCTANOIC ACID DERIVATIVE; PERFLUOROOCTANESULFONIC ACID; PERFLUOROOCTANOIC ACID;

ANTIBODY RESPONSE; ARTICLE; BIOACCUMULATION; BLOOD SAMPLING; CYTOKINE PRODUCTION; HUMORAL IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTOXICITY; POLYMERIZATION; WILDLIFE; ANIMAL; DRUG EFFECTS; HUMAN; IMMUNE SYSTEM; PHYSIOLOGY; TOXICITY;

ALKANESULFONIC ACIDS; ANIMALS; CAPRYLATES; FLUOROCARBONS; HUMANS; IMMUNE SYSTEM; PPAR ALPHA;

EID: 84907170034     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2014.01.038     Document Type: Article

References (83)

1. Alexander B.H. Study of Workers Employed at the 3M Cottage Grove Facility 2001, 3M Company, St. Paul, MN: Washington DC: U.S., EPA Public Docket AR-226-1030a018.
2. Alexander B.H., Olsen G.W. Bladder cancer in perfluorooctanesulfonyl fluoride manufacturing workers. Ann. Epidemiol. 2007, 17:471-478.
3. Biegel L.B., Hurtt M.E., Frame S.R., O'Connor J.C., Cook J.C. Mechanisms of extrahepatic tumor induction by peroxisome proliferators in male CD rats. Toxicol. Sci. 2001, 60:44-55.
4. Brieger A., Bienefeld N., Hasan R., Goerlich R., Haase H. Impact of perfluorooctanesulfonate and perfluorooctanoic acid on human peripheral leukocytes. Toxicol. In Vitro 2011, 25:960-968.
5. Butenhoff J.L., Gaylor D.W., Moore J.A., Olsen G.W., Rodricks J., Mandel J.H., Zobel L.R. Characterization of risk for general population exposure to perfluorooctanoate. Regul. Toxicol. Pharmacol. 2004, 39:363-380.
6. Cain L., Shankar A., Ducatman A.M., Steenland K. The relationship between serum uric acid and chronic kidney disease among Appalachian adults. Nephrol. Dial. Transplant. 2010, 25(11):3593-3599.
7. Calafat A.M., Ye X., Silva M.J., Kuklenyik Z., Needham L.L. Human exposure assessment to environmental chemicals using biomonitoring. Int. J. Androl. 2006, 29:166-171.
8. Calafat A.M., Kuklenyik Z., Reidy J.A., Caudill S.P., Tully J.S., Needham L.L. Serum concentrations of 11 polyfluoroalkyl compounds in the US population: data from the National Health and Nutrition examination survey. Environ. Sci. Technol. 2007, 41:2237-2242.
9. Cheung C., Akiyama T.E., Ward J.M., Nicol C.J., Feigenbaum L., Vinson C., Gonzalez F.J. Diminished hepatocellular proliferation in mice humanized for the nuclear receptor peroxisome proliferator-activated receptor-α. Cancer Res. 2004, 64:3849-3854.
10. Chinetti G., Fruchart J.C., Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm. Res. 2000, 49:497-505.
11. Corsini E., Avogadro A., Galbiati V., dell'Agli M., Marinovich M., Galli C.L., Germolec D.R. In vitro evaluation of the immunotoxic potential of perfluorinated compounds (PFCs). Toxicol. Appl. Pharmacol. 2011, 250:108-116.
12. Corsini E., Sangiovanni E., Avogadro A., Galbiati V., Viviani B., Marinovich M., Galli C.L., Dell'Agli M., Germolec D.R. In vitro characterization of the immunotoxic potential of several perfluorinated compounds (PFCs). Toxicol. Appl. Pharmacol. 2012, 258:248-255.
13. Costa G., Sartori S., Consonni D. Thirty years of medical surveillance in perfluooctanoic acid production workers. J. Occup. Environ. Med. 2009, 51:364-372.
14. Davis K.L., Aucoin M.D., Larsen B.S., Kaiser M.A., Hartten A.S. Transport of ammonium perfluorooctanoate in environmental media near a fluoropolymer manufacturing facility. Chemosphere 2007, 67:2011-2019.
15. Dewitt J.C., Copeland C.B., Strynar M.J., Luebke R.W. Perfluorooctanoic acid-induced immunomodulation in adult C57BL/6J or C57BL/6N female mice. Environ. Health Perspect. 2008, 116:644-650.
16. DeWitt J.C., Shnyra A., Badr M.Z., Loveless S.E., Hoban D., Frame S.R., Cunard R., Anderson S.E., Meade B.J., Peden-Adams M.M., Lubcke R.W., Luster M.I. Immunotoxicity of perfluorooctanoic acid and perfluorooctane sulfonate and the role of peroxisome proliferator-activated receptor alpha. Crit. Rev. Toxicol. 2009, 39:76-94.
17. DeWitt J.C., Copeland C.B., Luebke R.W. Suppression of humoral immunity by perfluorooctanoic acid is independent of elevation serum corticosterone concentration in mice. Toxicol. Sci 2009, 109:106-112.
18. DeWitt J.C., Shnyra A., Badr M.Z., Loveless S.E., Hoban D., Frame S.R., Cunard R., Anderson S.E., Meade B.J., Peden-Adams M.M., Luebke R.W., Luster M.I. Immunotoxicity of perfluorooctanoic acid and perfluorooctane sulfonate and the role of peroxisome proliferator-activated receptor alpha. Crit. Rev. Toxicol. 2009, 39:76-94.
19. DeWitt J.C., Peden-Adams M.M., Keller J.M., Germolec D.R. Immunotoxicity of perfluorinated compounds: recent developments. Toxicol. Pathol. 2012, 40:300-311.
20. Dietert R.R. Developmental immunotoxicology (DIT): windows of vulnerability, immune dysfunction and safety assessment. J. Immunotoxicol. 2008, 5:401-412.
21. Domingo J.L. Health risks of dietary exposure to perfluorinated compounds. Environ. Int. 2012, 40:187-195.
22. Dong G.H., Liu M.M., Wang D., Zheng L., Liang Z.F., Jin Y.H. Sub-chronic effect of perfluorooctanesulfonate (PFOS) on the balance of type 1 and type 2 cytokine in adult C57BL6 mice. Arch. Toxicol. 2011, 85:1235-1244.
23. EFSA Perfluorinated substances in food: occurrence and dietary exposure. EFSA J. 2012, 10:2743.
24. Emmett E.A., Zhang H., Shofer F.S., Freeman D., Rodway N.V., Desai C., Shaw L.M. Community exposure to perfluorooctanoate: relationships between serum levels and certain health parameters. J. Occup. Environ. Med. 2006, 48:771-779.
25. Eriksen K.T., Sørensen M., McLaughlin J.K., Lipworth L., Tjønneland A., Overvad K., Raaschou-Nielsen O. Perfluorooctanoate and perfluorooctanesulfonate plasma levels and risk of cancer in the general Danish population. J. Natl. Cancer Inst. 2009 Apr 15, 101(8):605-609.
26. Eriksen K.T., Raaschou-Nielsen O., McLaughlin J.K., Lipworth L., Tjønneland A., Overvad K., Sørensen M. Association between plasma PFOA and PFOS levels and total cholesterol in a middle-aged Danish population. PLoS One 2013, 8:e56969.
27. Fair P.A., Driscoll E., Mollenhauer M.A., Bradshaw S.G., Yun S.H., Kannan K., Bossart G.D., Keil D.E., Peden-Adams M.M. Effects of environmentally-relevant levels of perfluorooctane sulfonate on clinical parameters and immunological functions in B6C3F1 mice. J. Immunotoxicol. 2011, 8:17-29.
28. Fang X., Feng Y., Shi Z., Dai J. Alterations of cytokines and MAPK signaling pathways are related to the immunotoxic effect of perfluorononanoic acid. Toxicol. Sci. 2009, 108:367-376.
29. Faustman E.M., Omenn G.S. Risk assessment. Casarett and Doull's Toxicology: The Basic Science of Poisons 2001, 83-104. McGraw-Hill, New York. C.D. Klaassen (Ed.).
30. Fei C., McLaughlin J.K., Lipworth L., Olsen J. Prenatal exposure to PFOA and PFOS and risk of hospitalization for infectious diseases in early childhood. Environ. Res. 2012, 110:773-777.
31. Fletcher T., Steenland K., Savitz D. Status Report: PFOA and Immune Biomarkers in Adults Exposed to PFOA in Drinking Water in the Mid Ohio Valley 2009, Available at: http://www.c8sciencepanel.org/study_results.html.
32. Germolec D.E. Sensitivity and predictivity in immunotoxicity testing: immune endpoints and disease resistance. Toxicol. Lett. 2004, 149:109-114.
33. Gilliland F.D., Mandel J.S. Mortality among employees of a perfluorooctanoic acid production plant. J. Occup. Med. 1993, 35:950-954.
34. Gonzalez F.J., Peters J.M., Cattley R.C. Mechanism of action of thenon-genotoxic peroxisome proliferators: role of the peroxisome proliferator activator receptor alpha. J. Natl. Cancer Inst. 1998, 90:1702-1709.
35. Grandjean P., Wreford Andersen E., Budtz-Jorgensen E., Nielsen F., Molbak K., Wheihe P., Heilmann C. Serum vaccine antibody concentrations in children exposed to perfluorinated compounds. JAMA 2012, 307:391-397.
36. Granum B., Haug L.S., Namork E., Stolevik S.B., Thomsen C., Aagerge I.S., van Loveren H., Lovik M., Nygaard U.C. Pre-natal exposure to perfluoroalkyl substances may be associated with altered vaccine antibody levels and immune-related health outcomes in early childhood. J. Immunotoxicol. 2013, 10.3109/1547691X. 2012.755580.
37. Guruge K.S., Hikono H., Shimada N., Murakami K., Hasegawa J., Yeung L.W., Yamanaka N., Yamashita N. Effect of perfluorooctane sulfonate (PFOS) on influenza A virus-induced mortality in female B6C3F1 mice. J. Toxicol. Sci. 2009, 34:687-691.
38. Holsapple M.P., Paustenbach D.J., Chatnley G., West L.J., Luster M.I., Dietert R.R., Burns-Naas L.A. Symposium summary: children's health risk-what's so special about the developing immune system?. Toxicol. Appl. Pharmacol. 2004, 199:61-70.
39. Kato K., Calafat A.M., Wong L.Y., Wanigatunga A.A., Caudill S.P., Needham L.L. Polyfluoroalkyl compounds in pooled sera from children participating in the National Health and Nutrition Examination Survey 2001-2002. Environ. Sci. Technol. 2009, 43:2641-2647.
40. Kennedy G.L., Butenhoff J.L., Olsen O'Connor J.C., Seacat A.M., Perkins R.G., Biegel L.B., Murphy S.R., Farrar D.G. The toxicology of perfluorooctanoate. Crit. Rev. Toxicol. 2004, 34:351-384.
41. Lau C., Anitole K., Hodes C., Lai D., Pfahles-Hutchens A., Seed J. Perfluoroalkyl acids: a review of monitoring and toxicological findings. Toxicol. Sci. 2007, 99:366-394.
42. Lefebvre D.E., Curran I., Armstrong C., Coady L., Parenteau M., Liston V., Barker M., Aziz S., Rutherford K., Bellon-Gagnon P., Shenton J., Mehta R., Bondy G. Immunomodulatory effects of dietary potassium perfluorooctane sulfonate (PFOS) exposure in adult Sprague-Dawley rats. J. Toxicol. Environ. Health A 2008, 71:1516-1525.
43. Leonard R.C., Kreckmann K.H., Sakr C.J., Symons J.M. Retrospective cohort mortality study of workers in a polymer production plant including a reference population of regional workers. Ann. Epidemiol. 2008, 18:15-22.
44. Liu R.C., Hahn C., Hurtt M.E. The direct effect of hepatic peroxisome proliferators on rat Leydig cell function in vitro. Fundam. Appl. Toxicol. 1996, 30:102-108.
45. Liu R.C., Hurtt M.E., Cook J.C., Biegel L.B. Effect of the peroxisome proliferator, ammonium perfluorooctanoate (C8), on hepatic aromatase activity in adult male Crl:CDBR (CD) rats. Fundam. Appl. Toxicol. 1996, 30:220-228.
46. Loveless S.E., Hoban D., Sykes G., Frame S.R., Everds N.E. Evaluation of the immune system in rats and mice administered linear ammonium perfluorooctanoate (APFO). Toxicol. Sci. 2008, 105:86-96.
47. Lundin J.I., Alexander B.H., Olsen G.W., Church T.R. Ammonium perfluorooctanoate production and occupational mortality. Epidemiology 2009 Nov, 20(6):921-928.
48. Luster M.I., Portier C., Pait D.G., White K.L., Gennings C., Munson A.E., Rosenthal G.J. Risk assessment in immunotoxicology: I. Sensitivity and predictability of immune tests. Fundam. Appl. Toxicol. 1992, 18:200-210.
49. Luster M.I., Johnson V.J., Yucesoy B., Simeonova P.P. Biomarkers to assess potential developmental immunotoxicity in children. Toxicol. Appl. Pharmacol. 2005, 206:229-236.
50. Luster M.I., Portier C., Pait D.G., Rosenthal G.J., Germolec D.R., Corsini E., Blaylock B.L., Pollock P., Kouchi Y., Craig W., White K.L., Munson A.E., Comment C.E. Risk assessment in immunotoxicology. II. Relationships between immune and host resistance tests. Fundam. Appl. Toxicol. 1993, 21:71-82.
51. Okada E., Sasaki S., Saijo Y., Washino N., Miyashita C., Kobayashi S., Konishi K., Ito Y.M., Ito R., Nakata A., Iwasaki Y., Saito K., Nakazawa H., Kishi R. Prenatal exposure to perfluorinated chemicals and relationship with allergies and infectious diseases in infants. Environ. Res. 2012, 112(January):118-125. 10.1016/j.envres.2011.10.003.
52. Olsen G.W., Burris J.M., Mandel J.H., Zobel L.R. Serum perfluorooctane sulfonate and hepatic and lipid clinical chemistry tests in fluorochemical production employees. J. Occup. Environ. Med. 1999, 41:799-806.
53. Olsen G.W., Burris J.M., Ehresman D.J., Froehlich J.W., Seacat A.M., Butenhoff J.L., Zobel L.R. Half-life of serum elimination of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers. Environ. Health Perspect. 2007, 115:1298-1305.
54. Palmer C.N., Hsu M.H., Griffin K.J., Raucy J.L., Johnson E.F. Peroxisome proliferator activated receptor-alpha expression in human liver. Mol. Pharmacol. 1998, 53:14-22.
55. Pastoor T.P., Lee K.P., Perri M.A., Gillies P.J. Biochemical and morphological studies of ammonium perfluorooctanoate-induced hepatomegaly and peroxisome proliferation. Exp. Mol. Pathol. 1987, 47:98-109.
56. Peden-Adams M.M., Keil D.E., Romano T., Mollenhauer M.A.M., Fort D.J., Guiney P.D., Houde M., Kannan K., Muir D.C., Rice C.D., Stuckey J., Segars A.L., Scott T., Talent L., Bossart G.D., Fair P.A., Keller J.M. Health effects of perfluorinated compounds-what are the wildlife telling us?. Reprod. Toxicol. 2009, 27:414-415.
57. Peden-Adams M.M., EuDaly J.G., Dabra S., EuDaly A., Heesemann L., Smythe J., Keil D.E. Suppression of humoral immunity following exposure to the perfluorinated insecticide sulfluramid. J. Toxicol. Environ. Health A 2007, 70:1130-1141.
58. Peden-Adams M.M., Keller J.M., Eudaly J.G., Berger J., Gilkeson G.S., Keil D.E. Suppression of humoral immunity in mice following exposure to perfluorooctane sulfonate. Toxicol. Sci. 2008, 104:144-154.
59. Peden-Adams M.M., Mollenhauer M., Morse M., Wills L., Keil D.E. Effects of perfluorooctanesulfonic acid (PFOS) on NF-kB, AP-1, and PPAR-alpha. Toxicologist 2010, 114:330.
60. Peraza M.A., Burdick A.D., Marin H.E., Gonzalez F.J., Peters J.M. The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR). Toxicol. Sci. 2006, 90:269-295.
61. Post G.B., Louis J.B., Cooper K.R., Boros-Russo B.J., Lippincott R.L. Occurrence and potential significance of perfluorooctanoid acid (PFOA) detected in New Jersey public drinking water systems. Environ. Sci. Technol. 2009, 43:4547-4554.
62. Qazi M.R., Nelson B.D., Depierre J.W., Abedi-Valugerdi M. 28-Day dietary exposure of mice to a low total dose (7mg/kg) of perfluorooctanesulfonate (PFOS) alters neither the cellular compositions of the thymus and spleen nor humoral immune responses: does the route of administration play a pivotal role in PFOS-induced immunotoxicity?. Toxicology 2010, 267:132-139.
63. Rayne S., Forest K. Perfluoroalkyl sulfonic and carboxylic acids: a critical review of physicochemical properties, levels and patterns in waters and wastewaters, and treatment methods. J. Environ. Sci. Health A Tox. Hazard Subst. Environ. Eng. 2009, 44:1145-1199.
64. Saccani S., Pantano S., Natoli G. p38-Dependent marking of inflammatory genes for increased NF-kappa B recruitment. Nat. Immunol. 2002, 3:69-75.
65. Schmitz M.L., Bacher S., Kracht M. I kappa B-independent control of NF-kappa B activity by modulatory phosphorylations. Trends Biochem. Sci. 2001, 26:186-190.
66. Steenland K., Fletcher T., Savitz D.A. Epidemiologic evidence on the health effects of perfluorooctanoic acid (PFOA). Environ. Health Perspect. 2010, 118:1100-1108.
67. Suja F., Pramanik B.K., Zain S.M. Contamination, bioaccumulation and toxic effects of perfluorinated chemicals (PFCs) in the water environment: a review paper. Water Sci. Technol. 2009, 60:1533-1544.
68. Takacs M.L., Abbott B.D. Activation of mouse and human peroxisome proliferator-activated receptors (alpha, beta/delta, gamma) by perfluorooctanoic acid and perfluorooctane sulfonate. Toxicol. Sci. 2007, 95:108-117.
69. Ubel F.A., Sorenson S.D., Roach D.E. Health status of plant workers exposed to fluorochemicals-a preliminary report. Am. Ind. Hyg. Assoc. J. 1980, 41:584-589.
70. Vermeulen L., De Wilde G., Notebaert S., Vanden Berghe W., Haegeman G. Regulation of the transcriptional activity of the nuclear factor-kappaB p65 subunit. Biochem. Pharmacol. 2002, 64:963-970.
71. Vermeulen L., De Wilde G., Van Damme P., Vanden Berghe W., Haegeman G. Transcriptional activation of the NF-kappaB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1). EMBO J. 2003, 22:1313-1324.
72. van Loveren H., Germolec D., Koren H.S., Luster M.I., Nolan C., Repetto R., Smith E., Vos J.G., Vogt R.F. Report of the Bilthoven symposium: advancement of epidemiological studies in assessing the human health effects of immunotoxic agents in the environment and the workplace. Biomarkers 1999, 4:135-157.
73. Vestergren R., Cousins I.T. Tracking the pathways of human exposure to perfluorocarboxylates. Environ. Sci. Technol. 2009, 43:5565-5575.
74. U.S. Environmental Protection Agency Perfluorooctanoic Acid (PFOA) and Fluorinated Telomers 2010, www.epa.gov/opptintr/pfoa.
75. Yang Q., Xie Y., Depierre J.W. Effects of peroxisome proliferators on the thymus and spleen of mice. Clin. Exp. Immunol. 2000, 122:219-266.
76. Yang Q., Xie Y., Eriksson A.M., Nelson B.D., DePierre J.W. Further evidence for the involvement of inhibition of cell proliferation and development in thymic and splenic atrophy induced by the peroxisome proliferator perfluoroctanoic acid in mice. Biochem. Pharmacol. 2001, 62:1133-1140.
77. Yang Q., Xie Y., Alexson S.E.H., Nelson B.D., DePierre J.W. Involvement of the peroxisome proliferators-activated receptor-α in the immodulation caused by peroxisome proliferators in mice. Biochem. Pharmacol. 2002, 63:1893-1900.
78. Yang Q., Abedi-Valugerdi M., Xie Y., Zhao X., Moller G., Nelson B.D., DePierre J.W. Potent suppression of the adaptive immune response in mice upon dietary exposure to the potent peroxisome proliferators perfluorooctanoic acid. Int. Immunopharmacol. 2002, 2:389-397.
79. Wang I.J., Hsieh W.S., Chen C.Y., Fletcher T., Lien G.W., Chiang H.L., Chiang C.F., Wu T.N., Chen P.C. The effect of prenatal perfluorinated chemicals exposures on pediatric atopy. Environ. Res. 2011, 111:785-791.
80. Weihe P., Kato K., Calafat A.M., Nielsen F., Wanigatunga A.A., Needham L.L., Grandjean P. Serum concentrations of polyfluoroalkyl compounds in Faroese whale meat consumers. Environ. Sci. Technol. 2008, 42:6219-6295.
81. WHO Guidance for Immunotoxicity Risk Assessment for Chemicals 2012, World Health Organization, Geneva, IPCS harmonization project document; No 10. ISBN 978 92 4150 330 2.
82. Zareitalabad P., Siemens J., Hamer M., Amelung W. Perfluorooctanoic acid (PFOA) and perfluoroocanesulfonic acid (PFOS) in surface waters, sediments, soils and wastewater-a reveiw on concentrations and distributions coefficients. Chemosphere 2013, 91:725-732.
83. Zheng L., Dong G.H., Zhang Y.H., Liang Z.F., Jin Y.H., He Q.C. Type 1 and Type 2 cytokines imbalance in adult male C57BL/6 mice following a 7-day oral exposure to perfluorooctanesulfonate (PFOS). J. Immunotoxicol. 2011, 8:30-38.